Nanocomposites—materials in which nanoscale building blocks such as metal particles, ceramic phases, carbon structures or polymer networks are combined into a single functional system—have become indispensable across electronics, energy storage, medicine and environmental engineering. Their appeal lies in properties that no single component can deliver alone: enhanced mechanical strength, tailored electrical conductivity, catalytic activity and engineered optical performance. Yet synthesizing them with precise control over composition, morphology and interfacial chemistry remains one of the central challenges of materials science. The new review, led by Chenxing Liu and Dan Sun of Queen’s University Belfast alongside collaborators in France, China and the United Kingdom, makes the case that plasma-liquid systems are uniquely positioned to solve that problem.

The core of the technique is deceptively simple. When a plasma—an ionized gas containing electrons, ions, radicals and excited species—is generated in or above a liquid, it triggers a cascade of chemical reactions at the plasma-liquid interface and within the surrounding solution. Operating at room temperature and atmospheric pressure, these cold plasmas can drive reduction, polymerization, crosslinking and surface modification reactions simultaneously, all without the furnaces, vacuum chambers or toxic solvents that traditional synthesis routes typically require. The result is a one-step platform in which nanoparticles can be grown, functionalized and embedded directly into a matrix.

The review emphasizes that the real power of PiLC lies at the interface. The boundary between the plasma and the liquid is an extraordinarily reactive zone where electrons, ultraviolet radiation, solvated electrons, hydroxyl radicals and other reactive oxygen and nitrogen species converge. By tuning parameters such as plasma power, electrode geometry, gas composition and solution chemistry, researchers can steer which reactions dominate, and therefore control the size, shape and surface chemistry of the resulting nanomaterials. Surface modification, crosslinking and interfacial assembly—the three phenomena the authors single out—are what allow a nanocomposite’s final properties to be tailored with remarkable precision.

The breadth of materials accessible through the technique is striking. The review documents PiLC routes to polymer-matrix nanocomposites, in which nanoparticles are dispersed within or grafted onto polymers such as polyvinyl alcohol, polylactic acid, polypyrrole or poly(N-isopropylacrylamide). It also covers ceramic and metal oxide systems, where oxide nanoparticles and boron nitride nanosheets can be incorporated into hybrid architectures, and carbon-matrix composites spanning carbon nanotubes, graphene oxide, graphene quantum dots, carbon nanoballs and nanodiamonds. In many cases, the same plasma exposure that generates the nanoparticles also activates their surfaces, eliminating the separate functionalization steps that conventional synthesis usually demands.

Applications form the third pillar of the review. In energy storage, PiLC-synthesized nanocomposites are being explored as electrode materials where controlled interfaces between carbon, metal oxides and polymers can improve charge transport and cycling stability. In catalysis, the technique’s ability to produce metal nanoparticles with clean, highly active surfaces makes it attractive for electrocatalytic and photocatalytic reactions. Sensor development benefits from the platform’s capacity to decorate conductive polymer networks with metal nanoparticles, yielding materials with enhanced surface-enhanced Raman scattering performance and high sensitivity to target molecules. Biomedical applications are also emerging: plasma-treated polymer composites with tailored surface chemistry are being investigated for antimicrobial coatings, drug delivery vehicles and tissue-engineering scaffolds, aided by the fact that the synthesis route avoids elevated temperatures that would degrade sensitive biomolecules. Environmental remediation completes the list, with PiLC-made composites designed to adsorb or degrade pollutants in water.

What distinguishes PiLC from other plasma-based approaches, the authors argue, is its integration. Conventional nanoparticle synthesis might involve chemical reduction at high temperature, followed by ligand exchange, followed by dispersion into a polymer—a multi-step pipeline in which each stage introduces losses and variability. A solution plasma process can, in principle, accomplish nucleation, growth, functionalization and composite assembly in a single vessel. Dielectric barrier discharge configurations, cold atmospheric-pressure plasmas and microplasma systems each offer different operating regimes, giving chemists a toolbox of reactor designs matched to different materials and scales.

The review is not without caution, however. The authors identify process optimization, scalability and the fundamental understanding of plasma-liquid interactions as the field’s most pressing challenges. Plasma-liquid systems involve complex, coupled multiphysics: electric fields, gas dynamics, liquid-phase transport and reaction kinetics all interact in ways that are still only partially mapped. Diagnostics such as laser-induced fluorescence and spectroscopic measurements of plasma species are helping researchers build quantitative models, but predicting exactly how a given set of operating conditions will translate into a specific nanocomposite structure remains difficult. Reproducibility across laboratories, standardization of reactor designs and the translation from millilitre-scale demonstrations to industrially meaningful volumes are all hurdles that must be cleared before PiLC can move from the laboratory bench to the factory floor.

The timing of the review reflects growing momentum in plasma chemistry more broadly. Cold atmospheric-pressure plasmas have attracted attention for applications ranging from medical sterilization to agriculture, and the materials community has increasingly recognized that the same reactive species responsible for those effects—solvated electrons, hydroxyl radicals, atomic hydrogen, ultraviolet photons—can be harnessed as synthetic reagents. Because the process operates without bulk heating, it opens the door to composites containing thermally sensitive components that would be destroyed in a furnace or solvothermal reactor. It also aligns with sustainability goals: lower energy input, fewer solvent requirements and the potential to use benign precursor chemistries all count in its favor compared with high-temperature solid-state routes.

The international character of the research underscores the interdisciplinary nature of the field. The author team spans mechanical and aerospace engineering, biomedical engineering, pharmacy, chemistry and electrical engineering, drawing on institutions including Queen’s University Belfast, the CNRS/Université d’Orléans, Sichuan University, the University of Strathclyde, Beihang University and Henan University. That breadth mirrors the technique itself, which sits at the intersection of plasma physics, colloid chemistry, materials science and chemical engineering. Progress, the authors suggest, will require researchers from all those communities to share a common quantitative picture of what happens at the plasma-liquid interface.

Looking forward, the review sketches several promising trajectories. Machine-learning-assisted optimization of plasma parameters could compress the trial-and-error currently needed to find synthesis windows for new materials. In situ diagnostics combined with multiphysics modelling could turn plasma-liquid reactors from empirical black boxes into predictable, designable tools. And the expansion of PiLC into new material classes—metal-organic frameworks such as zeolitic imidazolate frameworks, doped quantum dots, and hybrid bio-inorganic assemblies—suggests the platform’s material palette is still growing. If the scalability challenge can be met, plasma-induced liquid chemistry could become a mainstream route to the nanocomposites that underpin next-generation batteries, catalysts, biosensors and medical devices, all manufactured under the gentlest of conditions: room temperature, ambient pressure, and nothing more exotic than a plasma and a solution.

The work, led by Azam Chahardoli of the Department of Biology at Razi University in Kermanshah, Iran, together with Ali Mostafaei of the Medical Biology Research Center at Kermanshah University of Medical Sciences, tackles one of the central challenges in nanomedicine: how to produce metallic nanoparticles that are stable, biocompatible, and functional without resorting to toxic synthetic reagents. Gold nanoparticles have long been celebrated for their chemical inertness, ease of synthesis, and utility in drug delivery, imaging, and photothermal therapy. Yet the capping and reducing agents traditionally used to keep them from clumping—citrate, thiols, or synthetic polymers—can introduce their own biological liabilities. Quercetin offers an elegant solution. As a polyphenolic flavonoid, it possesses multiple hydroxyl groups capable of reducing gold ions to metallic gold while simultaneously adsorbing onto the particle surface, acting as a built-in stabilizer and, in principle, a therapeutic payload in its own right.

The synthesis itself is deceptively simple in concept. When quercetin is introduced to a gold salt solution, the flavonoid’s phenolic groups donate electrons to gold ions, reducing them to gold atoms that nucleate and grow into nanoparticles. The quercetin molecules then coat the emerging particles, capping their surfaces and preventing aggregation through steric and electrostatic repulsion. The resulting quercetin-stabilized gold nanoparticles, or QU-GNPs, were characterized with a battery of analytical techniques that together paint a detailed portrait of their structure and behavior.

Ultraviolet-visible spectroscopy provided the first signature of success. The formation of gold nanoparticles is typically heralded by surface plasmon resonance—the collective oscillation of conduction electrons at the particle surface when struck by light—and the QU-GNPs displayed a maximum absorption peak at 532 nanometers, squarely in the range expected for well-dispersed spherical gold nanoparticles. X-ray diffraction confirmed a crystalline gold structure, with the diffraction pattern consistent with the face-centered cubic lattice of metallic gold. Field emission scanning electron microscopy revealed predominantly spherical particles with an average diameter of 33.1 plus or minus 9 nanometers, while transmission electron microscopy, which probes the particle core with higher resolution, determined a smaller average diameter of 21.93 nanometers. The discrepancy between the two measurements is telling: the organic quercetin shell adds thickness around the electron-dense gold core, and each technique weights that architecture differently.

Dynamic light scattering measurements yielded a zeta potential of negative 26.9 millivolts, a value comfortably within the range generally associated with colloidal stability. Particles with zeta potentials of this magnitude repel one another electrostatically, resisting the aggregation that would otherwise compromise their performance in biological fluids. Energy-dispersive X-ray spectroscopy and elemental mapping added the final chemical confirmation, identifying gold, carbon, and oxygen as the primary constituent elements. The presence of carbon and oxygen—elements absent from the gold salt itself—unequivocally demonstrated that quercetin moieties had successfully functionalized the nanoparticle surfaces, creating the organic-inorganic hybrid interface that underpins the material’s biological behavior.

With the material’s structure established, the team turned to its biological profile, and the results are remarkable in their breadth. Antioxidant activity was assessed using the DPPH assay, a standard test in which a stable free radical changes color as it is neutralized by antioxidants. The QU-GNPs scavenged 81.7 percent of DPPH radicals at a concentration of 600 micrograms per milliliter, an effect attributable to the hydrogen-donating capacity of the quercetin shell, whose phenolic hydroxyl groups quench radical species and interrupt oxidative chain reactions. Because oxidative stress is implicated in inflammation, aging, and cancer progression, this radical-scavenging capacity provides a mechanistic foundation for the compound’s broader therapeutic claims.

The blood-compatibility studies are particularly noteworthy, since many nanoparticles fail at precisely this hurdle. When human red blood cells were incubated with QU-GNPs at 800 micrograms per milliliter, hemolysis—the rupture of red cell membranes and release of hemoglobin—was only 1.6 percent, well below the 5 percent threshold conventionally considered non-hemolytic. But the nanoparticles did more than simply avoid damaging blood cells. At 100 micrograms per milliliter, they protected the integrity of the red blood cell membrane by 95.1 percent in the face of a hypotonic challenge, suggesting a membrane-stabilizing effect reminiscent of the way classical anti-inflammatory drugs protect lysosomal membranes. This dual behavior—harmless to healthy cells yet actively protective—is a rare and valuable combination.

The anti-inflammatory potential was further probed using a protein denaturation assay with bovine serum albumin. Protein denaturation is a well-established in vitro model for inflammation, as the denatured proteins generated at sites of tissue injury are thought to trigger autoimmune and inflammatory cascades. Diclofenac sodium, a widely prescribed non-steroidal anti-inflammatory drug, served as the benchmark. At 400 micrograms per milliliter, the QU-GNPs blocked protein denaturation by 90.5 percent, a figure that places the nano-compound in the same performance territory as clinical anti-inflammatory agents and underscores the pharmacological punch of the quercetin coating once displayed on a nanoparticle surface.

Cancer-cell testing delivered perhaps the most clinically tantalizing results. Using the MTT assay, which measures metabolic activity as a proxy for cell viability, the researchers evaluated the nanoparticles against MCF-7 cells, a widely used human breast cancer cell line, alongside normal fibroblast cells as a healthy-tissue control. The QU-GNPs exhibited a significant cytotoxic effect against the MCF-7 cells, with an inhibitory concentration of 293.6 micrograms per milliliter, while showing no toxic potential whatsoever toward normal fibroblasts. This selectivity—damaging cancer cells while leaving healthy cells untouched—is the holy grail of anticancer therapy and one of the most persistent challenges in chemotherapy. The flavonoid coating may contribute to this selectivity, as quercetin is known to modulate signaling pathways that are dysregulated in cancer cells, while the nanoparticle platform may enhance cellular uptake and localized delivery of the bioactive molecules.

Antibacterial activity rounded out the therapeutic panel. Although the nanoparticle platform was formulated with complementary medicine applications in mind rather than as a conventional antibiotic, the QU-GNPs displayed high antibacterial activity in the assays performed. Multiple mechanisms are likely at play: gold nanoparticles are known to physically interact with bacterial membranes, disrupting their integrity, while the quercetin coating contributes its own well-documented antimicrobial pharmacology, including inhibition of essential bacterial enzymes and interference with quorum sensing. In an era of rising antimicrobial resistance, any new antibacterial platform—particularly one derived from food-based biomolecules—warrants close attention.

Taken together, the findings position quercetin-stabilized gold nanoparticles as what the authors call a novel bio-safe bio/nano-compound with genuine bio-therapeutic potential. The concept is compelling precisely because of its economy: a single plant-derived molecule performs triple duty as reducing agent, stabilizer, and therapeutic cargo, eliminating the need for synthetic capping agents and embedding pharmacological activity directly into the nanoparticle architecture. The particle size, falling in the range where cellular uptake and biodistribution are favorable, and the strongly negative zeta potential, predicting colloidal stability in physiological environments, add engineering credibility to the biological promise.

The authors are careful to frame the work appropriately. All results to date come from in vitro assays—test-tube experiments with purified radicals, isolated red blood cells, albumin solutions, and cultured cells—and the pathway from such experiments to clinical therapies runs through extensive in vivo investigation. Pharmacokinetics, biodistribution, long-term toxicity, immune response, and efficacy in living organisms all remain to be established. The hemolysis experiments did involve human blood samples obtained from healthy volunteers with informed consent under approval from the Ethical Committee of Kermanshah University of Medical Sciences, lending clinical grounding to the biocompatibility data, but the leap from cell culture to patient remains substantial.

Nevertheless, the study stands as a vivid example of how green nanotechnology and complementary medicine can inform one another. Quercetin has been a staple of dietary supplement research for decades, celebrated for its antioxidant and anti-inflammatory properties but hampered by poor solubility and low bioavailability. Anchoring it to gold nanoparticles could, in principle, circumvent some of these limitations while adding the intrinsic capabilities of a nanoscale platform. If future in vivo studies bear out the promise suggested by these in vitro results, the humble flavonoid that gives red onions and apples their pigment may find itself at the center of a new generation of multi-functional nanomedicines—antioxidant, anti-inflammatory, anticancer, and antibacterial all at once, and built from one of nature’s most familiar molecules.